CONTEXT AND OBJECTIVES: Glycoprotein inhibitors (abciximab, eptifibatide and tirofiban) are used in patients with unstable angina and non-ST-segment elevation myocardial infarction before percutaneous coronary intervention. Of these, tirofiban is the least effective. We hypothesized that the response to tirofiban might be associated with glycoprotein gene mutations. DESIGN AND SETTING: Prospective study at Emergency Unit, Heart Institute (InCor), University of São Paulo. METHOD: Intrahospital evolution and platelet aggregation in response to tirofiban were analyzed in relation to four glycoprotein mutations in 50 patients indicated for percutaneous coronary intervention: 17 (34%) with unstable angina and 33 (66%) with non-ST-segment elevation myocardial infarction. Platelet aggregation was analyzed using the Born method. Blood samples were obtained before and one hour after tirofiban infusion. Glycoproteins Ia (807C/T), Ib (Thr/Met), IIb (Ile/Ser) and IIIa (PIA) were the mutations selected. RESULTS: Hypertension, dyslipidemia, diabetes, smoking, previous coronary artery disease and stroke were similar between the groups. Mutant glycoprotein IIIa genotypes had lower platelet aggregation before tirofiban administration than that of the wild genotype (41.0% ± 22.1% versus 55.9% ± 20.8%; P = 0.035). Mutant glycoprotein IIIa genotypes correlated moderately with lower platelet inhibition (r = -0.31; P = 0.030). After tirofiban administration, platelet glycoprotein Ia, Ib, IIb and IIIa mutations did not influence the degree of inhibition of platelet aggregation or intrahospital mortality. CONCLUSIONS: Mutations of glycoproteins Ia, Ib, IIb and IIIa did not influence platelet aggregation in response to tirofiban in patients with unstable angina and non-ST-segment elevation myocardial infarction.
INTRODUCTION
Tirofiban, a platelet surface receptor glycoprotein IIbIIIa (GPIIbIIIa) inhibitor, is recommended for patients with unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) before a planned percutaneous coronary intervention, in order to reduce periprocedural coronary events. GPIIbIIIa plays a central role in thrombus formation through binding fibrinogen, von Willebrand factor and fibronectin. 1 Tirofiban, like fibrinogen, has a similar affinity to the active GPIIbIIIa receptor. Thus, tirofiban binds to GPIIbIIIa and prevents formation of fibrinogen bridges, thereby reducing the thrombogenesis process. 2 Clinical studies have demonstrated the efficacy of tirofiban in reducing coronary events in patients with unstable angina and NSTEMI who undergo percutaneous coronary intervention. 3, 4 However, studies have shown unfavorable results from use of tirofiban for reducing ischemic events in patients undergoing percutaneous coronary intervention and also less inhibition of platelet aggregation with tirofiban, compared with two other commercially available inhibitors of platelet glycoprotein, abciximab and eptifibatide. 5, 6 The possibility of a paradoxical effect of platelet inhibitors on platelet aggregation has also been discussed. 7 The possible hypotheses for these findings relate to lower intensity of platelet inhibition, antagonist-induced platelet activation and interaction between platelets and inflammation. 8 Another hypothesis to explain the interindividual variability in the antiplatelet effect of tirofiban may involve platelet glycoprotein gene polymorphisms. 9 Mutations of GPIa (807C/T), Ib (Thr/Met), IIb (Ile/Ser) and IIIa (PIA) have been inconsistently associated with increased risk of major acute coronary events and resistance to antiplatelet drugs. 10, 11 We hypothesized that the smaller effect of tirofiban might be associated with platelet GP gene mutations. All the patients received 200 mg of aspirin or were put on aspirin at least 3 hours before tirofiban was started, along with heparin.
METHODS
Initially, a bolus dosage regimen of 0.4 µg/kg/min was given for 30 minutes, followed by a maintenance dose of 0.1 µg/kg/min for at least 24 hours.
High-risk unstable angina was defined as chest pain at rest lasting for more than 20 minutes, with dynamic electrocardiographic changes on the electrocardiogram and normal levels of MB isoenzyme of creatine kinase (CKMB) mass or troponin I.
NSTEMI was diagnosed when these findings were associated with increased blood levels of CKMB and troponin I. The clinical outcome was defined as in-hospital death from all causes.
The study was approved by the local institutional ethics committee. Informed consent was obtained from all patients.
Laboratory analysis
Troponin I and CKMB mass levels were analyzed in serum samples using specific kits, in the automated ADVIA Centaur equipment PA, USA) in accordance with the Born method. 13 The mixture was stirred at 37 °C using Teflon-coated magnetic rods, and aggregation curves were recorded using an aggregometer. The analysis was performed in duplicate, and the aggregation rate was measured from the maximum variation of light transmittance from the system.
Platelet glycoprotein genotype determination
Samples for DNA extraction were collected in EDTA tubes and maintained at 4 °C until use. Genomic DNA was isolated from peripheral blood lymphocytes in accordance with the method of Miller et al. 14 Platelet membrane glycoprotein Ia, Ibα, IIb and IIIa genotypes were analyzed by means of amplification of DNA using the polymerase chain reaction (PCR), as described in previously published methods, [15] [16] [17] and using the oligonucleotide sequencing primers described in Table 1 . The mutations analyzed were selected because these mutations present high frequency in our population.
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Genotyping of glycoprotein Ia (807C/T) polymorphism was performed by means of enzymatic digestion of a 115 bp fragment using Taq I at 37 °C, overnight, followed by identification of the fragments by means of electrophoresis on 2.5% agarose gel. IIIa. 17 The PCR reaction product, comprising a sequence of 266 bp of nucleotides was digested using MspI, at 37 °C overnight, followed 
Statistical analysis
The chi-square and Student t tests were used for baseline comparisons. Each GP mutation was divided into two genotype groups for bivariate analysis (homozygous wild versus heterozygous and homozygous mutants). The Spearman test was used for correlations between GP mutations and platelet inhibition data. Using in-hospital death as a dependent variable, we performed logistic regression that included independent variables with P < 0.25. The significance level used for the statistical tests was 5% (P < 0.05).
Statistical analyses were performed using the SAS for Windows software (Statistical Analysis System), version 9.2 (SAS Institute
Inc., 1989-1996; Cary, NC, USA).
RESULTS
The patients' mean age was 61.8 ± 11.7 years and 30 (60%)
were men. Hypertension, dyslipidemia, previous coronary artery disease and diabetes were highly prevalent among the patients and occurred, respectively, in 47 (94%), 39 (78%), 27
(54%) and 25 (50%) of the patients. The prevalence of diabetes was 25%, and 24% were active smokers. Previous stroke was reported by 10% of the patients. In-hospital death occurred in the cases of seven patients (14%): six (12%) due to cardiogenic shock, and one (2%) due to septicemia. The distributions of these data according to the genotype group (homozygous wild versus heterozygous and homozygous mutant) of each GP mutation are shown in Table 2 . The prevalences of hypertension, dyslipidemia, diabetes, smoking, previous coronary artery disease, previous stroke and all causes of death were similar between the groups. Platelet aggregations before tirofiban administration were also similar between the GPIa, Ib and IIb mutation groups, but not for the GPIIIa group. The GPIIIa mutation had lower baseline aggregation than the wild genotype (41.0% ± 22.1% versus 55.9% ± 20.8%; P = 0.035).
A moderate correlation was observed between GPIIIa mutation and baseline platelet aggregation (r = -0.31; P = 0.032).
After tirofiban administration, platelet GPIa, Ib, IIb and IIIa mutations did not alter inhibition of platelet aggregation or all causes of death ( Table 2) . Multivariate logistic regression did not reveal any GP mutation that was an independent variable for in-hospital death ( Table 3) .
DISCUSSION
The four polymorphisms of platelet glycoprotein analyzed in this study did not have any influence on the level of platelet inhibition in response to a standard dose of tirofiban, a specific inhibitor of GPIIbIIIa, in patients with acute coronary syndrome. The mutations analyzed were selected because these mutations present high frequency in our population. 11 The patients were treated in accordance with the guidelines of the American Heart Association for patients with unstable angina or NSTEMI. 5 Aspirin was administered at least three hours before introduction of tirofiban. Blood samples were obtained before and one hour after tirofiban administration, for analysis on platelet aggregation in response to tirofiban.
Oligonucleotides Primer sequences Size of product
Glycoprotein Ia Table 1 . Primer sequences and expected sizes of the products in base pairs (BP)
Prior tirofiban administration
There was a lower degree of inhibition of platelet aggregation with aspirin among the patients with the glycoprotein IIIa PLA2 mutation, before administration of tirofiban. This mutation was most often associated with increased resistance to inhibition among the platelet polymorphisms analyzed in this study. 18 
Szczeklik et al. assessed the association between genotypes with
PlA2 mutation and platelet aggregation in response to aspirin, in 80 healthy subjects. Individuals carrying the mutation PlA2 were associated with greater resistance of platelet aggregation to aspirin. 19 Among 82 patients on aspirin and clopidogrel, Angiolillo et al. showed that there was higher platelet aggregation in response to the agonists collagen, epinephrine and ADP, in patients with the GPIa C807T mutation. 20 Furthermore, Gonzalez-Conejero et al. did not observe any association between the mutations GPIIbIIIa PlA2 and GPIaIIa C807T and the efficacy of aspirin for platelet inhibition. 21 The effectiveness of platelet inhibition was higher among subjects treated with higher doses of aspirin.
These authors concluded that aspirin resistance was unlikely, but when it occurred, it would probably be dose-dependent and not influenced by mutations of GPIIbIIIa and GPIa/IIa.
The association between mutations of GPIIbIIIa and GPIa/ IIa and higher resistance of platelet inhibition to aspirin and clopidogrel is very questionable. Recent systematic reviews and meta-analyses by Floyd et al. showed conflicting associations between the GPIIIa PlA2 allele and resistance to antiplatelets and to cardiovascular diseases. 22 In these studies, the authors found an association between PlA2 mutation and ischemic stroke; however, no association was observed between the mutation and resistance to platelet inhibition with aspirin and clopidogrel, either in healthy subjects or in patients with cardiovascular diseases.
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After tirofiban administration
Our study showed that mutations of the glycoproteins analyzed did not influence platelet aggregation one hour after administration of tirofiban. However, it can be argued that inhibition of platelet aggregation using tirofiban is less effective than that of other GPIIbIIIa inhibitors. 5, 6, 24 This lower efficacy could be 28. GP = glycoprotein; 1 = homozygous wild; 2 = heterozygous; 3 = homozygous mutant; UA = unstable angina; AMI = acute myocardial infarction; M = male; F = female; CAD = coronary artery disease; CK = creatine kinase. Value in parentheses are percentages. Table 2 . Demographic variables and laboratory data relating to 50 patients with unstable angina and non-ST-segment elevation myocardial infarction *P = 0.035; GP = glycoprotein; 1 = homozygous wild; 2 = heterozygous; 3 = homozygous mutant; one-hour aggregation and inhibition (%) refer to the percentage aggregation or inhibition one hour after tirofiban administration. Value in parentheses are percentages. Table 3 . Aggregation data and incidence of death among 50 patients with unstable angina and non-ST-segment elevation myocardial infarction be an association between this mutation and coronary thrombosis. 25 Wheeler et al. showed that there was less platelet inhibition through using abciximab in patients with the PlA2 mutation who underwent percutaneous coronary intervention. 26 Weber et al.
conducted an in vitro study on the antiplatelet effects of three 28 Aggregation tests were performed at baseline and after 10 min, 1 h and 4 h after GPIIbIIIa inhibitor administration.
PlA2 mutation was present in 26 patients (32.5%). The clinical and angiographic features were similar between groups of carriers and noncarriers of the PLA2 mutation, except with regard to in-stent restenosis, which was more frequent among patients with PlA2. The PlA2 mutation did not affect the platelet response to GPIIbIIIa inhibitors.
Although the initial studies signaled that genetic polymorphisms of platelet glycoproteins had an influence on platelet response, this interaction was not observed in our study or proven by other more recent studies. [25] [26] [27] [28] However, variability of platelet response to GPIIbIIIa inhibitors exists and can be correlated with other factors, such as drug dose-dependence, the method used to assess platelet aggregation, pharmacodynamics, concomitant use of dual antiplatelet aggregation, rheological characteristics of blood coagulation and other such things. Khaspekova et al. analyzed the platelet response among patients with acute coronary syndrome and found that the expression of platelet GPIb and GPIIbIIIa correlated with the average volume of platelets and not the genetic polymorphism of the GPIIIa Leu33Pro and GPIbα Thr145Met mutations. 29 Schneider et al. showed that the lesser degree of initial inhibition of platelet aggregation using tirofiban was dose-dependent compared to abciximab. " 30 A recent meta-analysis showed that there was a reduction in major adverse coronary events through addition of tirofiban to aspirin and clopidogrel, among patients with ST-elevation myocardial infarction prior to percutaneous coronary intervention. 31 Blood rheological changes, such as blood viscosity, increased serum levels of fibrinogen, inflammatory cytokines and others, could explain the variability of platelet response. It is well known that these factors favor thrombotic process by acting at various levels of the coagulation system.
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CONCLUSION
In conclusion, this study showed that the GPIa, Ib, IIb and IIIa mutations analyzed did not influence platelet aggregation in response to tirofiban in patients with acute coronary syndrome.
This result suggests that, despite the possibility that interindivid- 
